Editor’s note: Related tickers: Lentuo International Inc (ADR) (NYSE:LAS), Nam Tai Electronics, Inc. (NYSE:NTE), China Hgs Real Estate Inc (NASDAQ:HGSH), Greenway Medical Technologies, Inc. (NYSE:GWAY), Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)
Even though there are price gainers and volume leaders, the top losers must also be watched. On Monday, the top five losers are: Lentuo International Inc (ADR) (NYSE:LAS), Nam Tai Electronics, Inc. (NYSE:NTE), China Hgs Real Estate Inc (NASDAQ:HGSH), Greenway Medical Technologies, Inc. (NYSE:GWAY), and Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX),
Lentuo International Inc (ADR) (NYSE:LAS) slid by 31.30% to $1.80 in deals worth $370,900. According to a statement on PRNewswire, Lentuo International Inc (ADR) (NYSE:LAS) today posted the financial results for the fourth quarter of 2012 and for the entire last year. The revenue in the fourth quarter fell by 15.4% on the year to $140.8 million, while the net loss totalled $3.9 million, compared to a profit of $2.5 million. Over the whole 2012, the revenue grew by 7.5% to $524.1 million, the statement added.
In turnover worth almost $7.4 million, Nam Tai Electronics, Inc. (NYSE:NTE) has lost 29.48% to $7.99. Today, Nam Tai Electronics, Inc. (NYSE:NTE) released its financial results for the first three months of 2013. The net sales advanced to $177.5 million, higher compared to $87.8 million in the first quarter of the previous year. The net income totalled almost $5.0 million, against a loss of $3.6 million, Nam Tai Electronics, Inc. (NYSE:NTE) said in a statement.
China Hgs Real Estate Inc (NASDAQ:HGSH) declined by 25.51% to $9.11. China Hgs Real Estate Inc (NASDAQ:HGSH) is specialized in real estate development, construction and sale of residential apartments, parking as well as commercial properties.
Greenway Medical Technologies, Inc. (NYSE:GWAY) fell by 19.07% to $12.99 in turnover of about $887,900. In a statement issued today, Greenway Medical Technologies, Inc. (NYSE:GWAY), has reviewed its outlook for the fiscal year that will end on June 30, 2013. The company forecasts a revenue between $132 million and $134 million and an adjusted EBITDA of between %5.8 million to $6.8 million.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) decreased by 18.86% to $1.85 in deals worth $3.2 million. The Street said in a story today that Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) could suffer after Merck & Co., Inc. (NYSE:MRK) and Pfizer Inc. (NYSE:PFE) announced about signing a partnership agreement for the development of Pfizer Inc. (NYSE:PFE)’s ertugliflozin which is being evaluated for the cure of type 2 diabetes. Since Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is designing a similar drug, LX4211, it could have some difficulties finding a partner to help cover the costs of research, The Street said.
Disclosure: none
